t
On June 14, 2023, IXICO plc announced that an existing client contracted the company to provide imaging services for the extension study of their Huntington's disease Ph2b trial. This new work order is worth just under £2M, which IXICO expects to deliver over the next 4 years.
| Date | 14 Jun 2023 |
| Time | 07:00:04 |
| Category | Corporate updates |
| ID | 5944C |
14 June 2023
IXICO plc
("IXICO", the "Company" or the "Group")
Contract win in Huntington's disease worth circa £2M
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, is pleased to announce that an existing client has contracted IXICO to provide imaging services for the extension study of their Huntington's disease ('HD') Ph2b trial. This is a new study protocol and results in a new work order worth just under £2M which IXICO expects to deliver over the next 4 years.
HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this contract to support the ongoing development programme of this promising treatment in HD. This contract strengthens our order book, securing further visibility to future anticipated revenues. We have been working with this client for several years and I am delighted to be further deepening our long-term partnership as they pursue a treatment for this terrible neurological disease."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
For further information please contact:
|
IXICO plc |
+44 (0)20 3763 7499 |
|
|
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
|
|
|
Cenkos Securities PLC (Nominated adviser and sole broker)
|
+44 (0)20 7397 8900 |
|
|
Giles Balleny / Max Gould (Corporate Finance) |
|
|
|
Michael F Johnson / Tamar Cranford-Smith (Sales)
|
|
|
|
|
|
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.